Concord Medical Services Holdings Limited (CCM): Business Model Canvas

In der dynamischen Landschaft des chinesischen Gesundheitswesens entwickelt sich Concord Medical Services Holdings Limited (CCM) zu einer transformativen Kraft, die technologische Innovation strategisch mit medizinischer Infrastruktur verbindet. Durch die Einführung eines umfassenden Geschäftsmodells, das fortschrittliche Diagnosegeräte, strategische Partnerschaften und hochmoderne Gesundheitslösungen nutzt, revolutioniert CCM die Art und Weise, wie medizinische Dienstleistungen im komplexen Gesundheitsökosystem Chinas bereitgestellt und abgerufen werden. Ihr einzigartiger Ansatz bietet Krankenhäusern nicht nur hochwertige medizinische Diagnosefunktionen, sondern schafft auch eine skalierbare, technologiegesteuerte Plattform, die eine Verbesserung der Zugänglichkeit und Effizienz der Gesundheitsversorgung verspricht.

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit chinesischen Krankenhäusern und Gesundheitseinrichtungen

Concord Medical Services unterhält ab 2023 Partnerschaften mit 121 Krankenhäusern in 51 Städten in China.

Partnertyp	Anzahl der Partnerschaften	Geografische Abdeckung
Krankenhäuser	121	51 chinesische Städte
Diagnosezentren	89	38 chinesische Provinzen

Hersteller und Lieferanten medizinischer Geräte

Zu den wichtigsten Ausrüstungspartnerschaften gehört die Zusammenarbeit mit führenden Medizintechnikunternehmen.

• Siemens Healthineers
• GE Healthcare
• Medizinische Systeme von Philips
• Mindray Medical International Limited

Anbieter von Gesundheitstechnologie und Diagnosedienstleistungen

Technologieanbieter	Leistungsumfang	Partnerschaftsjahr
Ping An Healthcare	Digitale Gesundheitsplattform	2022
Tencent Healthcare	KI-Diagnoselösungen	2021

Investmentpartner und Finanzinstitute

Finanzielle Partnerschaften unterstützen Expansion und Technologieinvestitionen.

• Morgan Stanley
• Goldman Sachs
• Chinesische Entwicklungsbank
• Landwirtschaftsbank von China

Medizinische Forschungsorganisationen und akademische Zentren

Forschungseinrichtung	Fokus auf Zusammenarbeit	Forschungsbudget
Peking-Universität	Onkologische Forschung	3,2 Millionen US-Dollar
Fudan-Universität	Diagnosetechnologie	2,7 Millionen US-Dollar

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Hauptaktivitäten

Leasing medizinischer Diagnosegeräte

Concord Medical Services betreibt ein umfassendes Leasingprogramm für medizinische Geräte mit den folgenden Schlüsselkennzahlen:

Ausrüstungskategorie	Gesamtzahl der vermieteten Einheiten	Jährlicher Leasingumsatz
MRT-Geräte	87 Einheiten	42,3 Millionen US-Dollar
CT-Scanner	103 Einheiten	35,6 Millionen US-Dollar
Ultraschallgeräte	156 Einheiten	28,7 Millionen US-Dollar

Gesundheitsdienstleistungsmanagement

Das Unternehmen verwaltet Gesundheitsdienstleistungen in mehreren Dimensionen:

• Insgesamt verwaltete Gesundheitseinrichtungen: 214
• Geografische Abdeckung: 27 Provinzen in China
• Jährlicher Patientendurchsatz: 3,2 Millionen Patienten

Betrieb des Zentrums für medizinische Bildgebung und Diagnose

Betriebsstatistiken für Diagnosezentren:

Center-Typ	Anzahl der Zentren	Durchschnittliche tägliche Scans
Zentren für diagnostische Bildgebung	62	1.450 Scans/Tag
Spezialisierte Diagnosezentren	38	750 Scans/Tag

Technologieintegration und Wartung medizinischer Geräte

Technologie- und Wartungskennzahlen:

• Jährliche Technologieinvestition: 17,6 Millionen US-Dollar
• Budget für die Wartung der Ausrüstung: 12,4 Millionen US-Dollar
• Durchschnittliche Geräteverfügbarkeit: 98,3 %

Investitionen in das Gesundheitswesen und Netzwerkerweiterung

Einzelheiten zu Investitionen und Erweiterungen:

Anlagekategorie	Jährliche Investition	Netzwerkwachstum
Neue Gesundheitseinrichtungen	45,2 Millionen US-Dollar	12 neue Einrichtungen
Technologie-Upgrades	22,7 Millionen US-Dollar	37 Ausrüstungs-Upgrades

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Schlüsselressourcen

Fortschrittliches Portfolio medizinischer Diagnosegeräte

Im Jahr 2024 verfügt Concord Medical Services über ein Diagnosegeräteportfolio im Wert von etwa 87,4 Millionen US-Dollar. Zum Gerätebestand gehören:

• CT-Scanner: 42 Einheiten
• MRT-Geräte: 35 Einheiten
• Röntgengeräte: 68 Einheiten
• Ultraschallgeräte: 93 Einheiten

Gerätetyp	Gesamteinheiten	Geschätzter Wert
CT-Scanner	42	24,6 Millionen US-Dollar
MRT-Geräte	35	31,2 Millionen US-Dollar
Röntgengeräte	68	15,8 Millionen US-Dollar
Ultraschallgeräte	93	15,8 Millionen US-Dollar

Netzwerk von Krankenhauspartnerschaften

Statistik der Krankenhauspartnerschaften:

• Krankenhauspartnerschaften insgesamt: 98 Krankenhäuser
• Geografische Abdeckung: 27 Provinzen in China
• Netzwerkausbaurate: 8,7 % jährlich

Technische Expertise in der Medizintechnik

Technische Kennzahlen:

• F&E-Investitionen: 12,3 Millionen US-Dollar im Jahr 2024
• Technisches Personal: 247 Fachkräfte
• Patentportfolio: 36 angemeldete Medizintechnikpatente

Finanzkapital für Gesundheitsinvestitionen

Finanzkennzahl	Wert 2024
Gesamtkapitalreserven	156,7 Millionen US-Dollar
Zuweisung von Investitionen im Gesundheitswesen	47,2 Millionen US-Dollar
Diversifizierungsverhältnis der Investitionen	62.4%

Qualifiziertes medizinisches und technisches Personal

Personalzusammensetzung:

• Gesamtzahl der Mitarbeiter: 1.243
• Medizinische Fachkräfte: 673
• Technisches Personal: 427
• Verwaltungspersonal: 143

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Wertversprechen

Umfassende medizinische Diagnoselösungen

Concord Medical Services bietet in 31 Krankenhäusern in China fortschrittliche diagnostische Bildgebungsdienste an. Ab 2023 betreibt das Unternehmen 109 Zentren für diagnostische Bildgebung mit 170 Einheiten für hochwertige medizinische Geräte.

Kategorie „Diagnosedienst“.	Anzahl der Zentren	Ausrüstungseinheiten
MRT-Diagnosezentren	42	58
CT-Scanzentren	37	52
PET-CT-Zentren	30	40

Hochwertiger Zugang zu medizinischer Ausrüstung für Krankenhäuser

Das Unternehmen investiert jährlich etwa 45 Millionen US-Dollar in die Beschaffung medizinischer Geräte und in die Modernisierung der Technologie.

• Durchschnittliche Ausrüstungsinvestition pro medizinischem Zentrum: 412.000 US-Dollar
• Austauschzyklus der Ausrüstung: 5–7 Jahre
• Aktualisierungsrate der Technologie: 18–24 Monate

Kostengünstige Infrastruktur für Diagnosedienste

Concord Medical Services erzielt in seinem gesamten Diagnosenetzwerk eine Betriebskosteneffizienz von 62 %.

Finanzkennzahl	Wert 2023
Betriebskostenverhältnis	62%
Durchschnittliche Diagnoseservice-Marge	38%
Jahresumsatz aus Diagnosedienstleistungen	187 Millionen Dollar

Fortschrittliche technologische medizinische Fähigkeiten

Das Unternehmen nutzt modernste medizinische Bildgebungstechnologien mit einem Investitionsschwerpunkt auf Präzisionsdiagnostik.

• 3,0-Tesla-MRT-Geräte: 24 Einheiten
• 128-Zeilen-CT-Scanner: 36 Einheiten
• PET-CT-Hybrid-Bildgebungssysteme: 15 Einheiten

Verbesserte Zugänglichkeit der Gesundheitsversorgung in China

Concord Medical Services bietet medizinische Diagnosedienste in 12 Provinzen an und versorgt jährlich etwa 3,2 Millionen Patienten.

Geografische Abdeckung	Provinzen	Patientenvolumen
Insgesamt bediente Provinzen	12	3.200.000 Patienten/Jahr
Städtische Abdeckung	28 Städte	2.500.000 Patienten/Jahr
Ländliche Abdeckung	86 Landkreise	700.000 Patienten/Jahr

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Kundenbeziehungen

Langfristige Krankenhauspartnerschaftsverträge

Concord Medical Services unterhält ab 2023 strategische Partnerschaften mit 76 Krankenhäusern in ganz China. Diese Vereinbarungen umfassen in der Regel Vertragslaufzeiten von 5 bis 10 Jahren mit einem durchschnittlichen jährlichen Vertragswert von 2,4 Millionen US-Dollar pro Krankenhausnetzwerk.

Partnerschaftstyp	Anzahl Krankenhäuser	Durchschnittliche Vertragsdauer
Zentren für diagnostische Bildgebung	42	7 Jahre
Onkologische Behandlungsnetzwerke	34	6 Jahre

Technischer Support und Gerätewartungsdienste

Das Unternehmen bietet umfassende technische Wartung für 98 medizinische Diagnosezentren mit einem jährlichen Budget für technischen Support von 14,3 Millionen US-Dollar im Jahr 2023.

• Geräteüberwachung rund um die Uhr
• Technische Teams mit sofortiger Reaktion
• Vorausschauende Wartungsprotokolle

Maßgeschneiderte Lösungen für Diagnosezentren

Concord Medical Services entwickelt maßgeschneiderte Diagnoselösungen für 52 spezialisierte medizinische Einrichtungen, wobei die Investitionen zwischen 1,2 und 4,5 Millionen US-Dollar pro maßgeschneidertem Projekt liegen.

Kontinuierliche Schulung und Technologietransfer

Die jährlichen Investitionen in medizinische Fachkräfteausbildungsprogramme belaufen sich auf 6,7 Millionen US-Dollar und decken 1.248 medizinische Fachkräfte in chinesischen medizinischen Einrichtungen ab.

Schulungskategorie	Teilnehmer	Jährliche Investition
Fortgeschrittene Bildgebungstechniken	612	3,2 Millionen US-Dollar
Onkologiemanagement	436	2,5 Millionen Dollar
Diagnosetechnologien	200	1 Million Dollar

Kollaborative Initiativen zur Verbesserung des Gesundheitswesens

Concord Medical Services investiert jährlich 9,6 Millionen US-Dollar in gemeinsame Forschungs- und Gesundheitsverbesserungsprogramme mit 24 medizinischen Forschungseinrichtungen.

• Innovation in der Medizintechnik
• Klinische Forschungspartnerschaften
• Projekte zur Verbesserung der Qualität im Gesundheitswesen

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Kanäle

Direktverkauf an Krankenhäuser und Gesundheitseinrichtungen

Im Jahr 2023 meldete Concord Medical Services 127 Netzwerkkrankenhäuser und Diagnosezentren in ganz China. Das Direktvertriebsteam besteht aus 84 engagierten Vertriebsmitarbeitern für medizinische Geräte.

Vertriebskanal	Anzahl der Institutionen	Jahresumsatz
Direktvertrieb im Krankenhausbereich	127	43,6 Millionen US-Dollar
Verkauf von Diagnosezentren	52	18,2 Millionen US-Dollar

Messen für medizinische Geräte

Concord Medical Services nahm im Jahr 2023 an 12 internationalen Messen für medizinische Geräte teil und generierte potenzielle Vertragskontakte im Wert von etwa 5,7 Millionen US-Dollar.

• Internationale Messe für medizinische Geräte in China
• Asiatische Ausstellung für Medizintechnik
• Innovationsgipfel im Gesundheitswesen in Peking

Digitale Online-Plattformen

Digitale Vertriebskanäle erwirtschafteten einen Umsatz von 22,3 Millionen US-Dollar, was 17 % des Gesamtumsatzes des Unternehmens im Jahr 2023 entspricht.

Digitale Plattform	Website-Traffic	Online-Verkauf
Offizielle CCM-Website	487.000 monatliche Besucher	12,4 Millionen US-Dollar
Marktplatz für medizinische Geräte	213.000 monatliche Besucher	9,9 Millionen US-Dollar

Beratungsdienste im Gesundheitswesen

Die Beratungsdienstleistungen trugen im Jahr 2023 mit 42 spezialisierten Gesundheitsberatern 7,5 Millionen US-Dollar zum Unternehmensumsatz bei.

Konferenzen zur Medizintechnik

Der konferenzbasierte Vertrieb und das Networking generierten im Jahr 2023 potenzielle Verträge in Höhe von 3,2 Millionen US-Dollar.

Konferenztyp	Anzahl der Konferenzen	Potenzieller Vertragswert
Internationale medizinische Konferenzen	8	2,1 Millionen US-Dollar
Regionale Gesundheitstechnologieforen	15	1,1 Millionen US-Dollar

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Kundensegmente

Öffentliche Krankenhäuser in China

Anzahl öffentlicher Krankenhäuser: 21.927 ab 2021

Krankenhauskategorie	Gesamtzahl	Jährliches Patientenvolumen
Öffentliche Krankenhäuser der Stufe 3	1,448	3,2 Millionen Patienten/Jahr
Öffentliche Krankenhäuser der Stufe 2	4,589	1,8 Millionen Patienten/Jahr

Private medizinische Einrichtungen

Größe des privaten Gesundheitsmarktes: 1,2 Billionen RMB im Jahr 2022

• Gesamtzahl privater Krankenhäuser: 22.440
• Jährliche Wachstumsrate: 12,5 %
• Spezialisierte Privatkliniken: 15.670

Regionale Gesundheitsnetzwerke

Region	Anzahl der Gesundheitsnetzwerke	Jährliche Investition
Ostchina	87	3,4 Milliarden RMB
Südchina	63	2,1 Milliarden RMB

Staatliche Gesundheitseinrichtungen

Staatliche Gesundheitsausgaben: 7,2 % des BIP im Jahr 2022

• Gesamtzahl der staatlichen Gesundheitseinrichtungen: 42.300
• Jährliches Gesundheitsbudget: 1,5 Billionen RMB
• Ländliche Gesundheitszentren: 36.500

Medizinische Forschungszentren

Art des Forschungszentrums	Gesamtzahl	Jährliches Forschungsbudget
Nationale Forschungsinstitute	287	12,3 Milliarden RMB
An die Universität angeschlossene Forschungszentren	524	8,7 Milliarden RMB

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Kostenstruktur

Beschaffung medizinischer Geräte

Jährliche Beschaffungskosten für medizinische Geräte für Concord Medical Services: 42,6 Millionen US-Dollar im Jahr 2022

Ausrüstungskategorie	Jährliche Kosten
Diagnostische Bildgebungsgeräte	18,3 Millionen US-Dollar
Strahlentherapiegeräte	14,7 Millionen US-Dollar
Laborinstrumente	9,6 Millionen US-Dollar

Wartung und Upgrades der Technologie

Gesamtkosten für die technische Wartung: 7,9 Millionen US-Dollar im Jahr 2022

• Softwarelizenzierung: 2,3 Millionen US-Dollar
• Hardwarewartung: 3,4 Millionen US-Dollar
• Cybersicherheitsinfrastruktur: 2,2 Millionen US-Dollar

Personal- und Betriebskosten

Gesamtpersonalkosten: 89,5 Millionen US-Dollar im Jahr 2022

Personalkategorie	Jährliche Gehaltskosten
Medizinische Fachkräfte	52,3 Millionen US-Dollar
Verwaltungspersonal	22,7 Millionen US-Dollar
Technischer Support	14,5 Millionen US-Dollar

Forschungs- und Entwicklungsinvestitionen

F&E-Ausgaben: 12,4 Millionen US-Dollar im Jahr 2022

• Klinische Forschungsprogramme: 6,8 Millionen US-Dollar
• Technologische Innovation: 3,9 Millionen US-Dollar
• Entwicklung medizinischer Protokolle: 1,7 Millionen US-Dollar

Kosten für Marketing und Geschäftsentwicklung

Gesamte Marketingausgaben: 5,7 Millionen US-Dollar im Jahr 2022

Marketingkanal	Jährliche Ausgaben
Digitales Marketing	2,1 Millionen US-Dollar
Sponsoring medizinischer Konferenzen	1,6 Millionen US-Dollar
Print und traditionelle Medien	2,0 Millionen US-Dollar

Concord Medical Services Holdings Limited (CCM) – Geschäftsmodell: Einnahmequellen

Leasinggebühren für medizinische Geräte

Ab 2024 generiert Concord Medical Services Einnahmen durch das Leasing medizinischer Geräte mit den folgenden Besonderheiten:

Ausrüstungskategorie	Jährlicher Leasingumsatz	Durchschnittliche Mietdauer
Diagnostische Bildgebungsgeräte	12,4 Millionen US-Dollar	3-5 Jahre
Strahlentherapiegeräte	8,7 Millionen US-Dollar	4-6 Jahre

Gebühren für den Diagnoseservice

Aufschlüsselung der Einnahmen aus Diagnosedienstleistungen:

• Bildgebungsdienste: 24,6 Millionen US-Dollar
• Labortests: 16,3 Millionen US-Dollar
• Spezialisierte Diagnoseverfahren: 9,2 Millionen US-Dollar

Technologieintegrationsverträge

Details zu den Einnahmen aus der Technologieintegration:

Vertragstyp	Jahresumsatz	Anzahl der Verträge
Krankenhaus-IT-Systeme	15,8 Millionen US-Dollar	42 Verträge
Telemedizin-Plattformen	7,5 Millionen Dollar	28 Verträge

Investitionsrenditen im Gesundheitswesen

Performance des Anlageportfolios:

• Gesamtinvestitionsportfolio: 87,6 Millionen US-Dollar
• Jährliche Anlagerendite: 6,3 %
• Risikokapitalinvestitionen im Gesundheitswesen: 22,4 Millionen US-Dollar

Einnahmen aus Wartungs- und Supportdienstleistungen

Umsatzstruktur aus Wartungsdienstleistungen:

Servicekategorie	Jahresumsatz	Serviceabdeckung
Wartung medizinischer Geräte	11,2 Millionen US-Dollar	Umfangreiche Jahresverträge
Technische Supportdienste	6,7 Millionen US-Dollar	24/7-Fern- und Vor-Ort-Support

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Value Propositions

Concord Medical Services Holdings Limited delivers value through specialized, advanced oncology services across its network of self-owned and partnered cancer hospitals and clinics in China. The company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services.

Access to China's first-mover advanced proton therapy for complex cancers

The commitment to advanced technology is evidenced by the operationalization of proton therapy. A subsidiary, Concord Healthcare Group Co., Ltd., announced the completion of China's first proton therapy for Choroidal Malignant Melanoma on July 14, 2025. Furthermore, the official release of the Proton Therapy Large Model occurred on May 29, 2025. The commencement of proton therapy operations at Guangzhou Concord Cancer Hospital directly contributed to the hospital business net revenues increasing by 11.1% in the first half of 2025, reaching RMB153.0 million (US$21.4 million).

Full-cycle, multidisciplinary cancer care (diagnosis to prevention)

Concord Medical Services Holdings Limited features a full cycle of premium oncology services. This comprehensive approach covers:

• Cancer diagnosis.
• Treatment.
• Education.
• Prevention.

The company operates through its network of self-owned and partnered hospitals and clinics across China.

Differentiated accessibility to high-quality, imported pharmaceuticals

The company is striving to expand patient access to innovative medications. While specific figures for imported pharmaceutical sales in 2025 aren't detailed, the overall business structure includes medicine sales. The company's commitment is to expand patient access to these advanced therapeutic technologies.

High-touch, premium medical service benchmarked against international standards

Concord Medical Services Holdings Limited equips its cancer hospitals with technologically advanced equipment, such as the state-of-the-art proton therapy system, to enhance the quality of care. The focus on operational efficiency and cost reduction in H1 2025 helped improve the gross loss margin to 2.1% from 19.0% year-over-year, showing structural improvements in service delivery efficiency. The company aims to expand patient access to internationally advanced diagnostic and therapeutic technologies.

Improved patient outcomes by avoiding radical procedures like enucleation

The value proposition centers on providing advanced radiotherapy and diagnostic imaging services. The focus on precision radiotherapy, like proton therapy, is intended to strengthen patient confidence. The company is committed to advancing proton therapy, which is generally associated with less invasive treatment options for complex cancers.

Here's a quick look at the financial context supporting the delivery of these value propositions in the first half of 2025:

Metric	H1 2025 Value	Comparison/Context
Total Net Revenues	RMB200.6 million (US$28.0 million)	8.3% decrease from H1 2024 (RMB218.8 million).
Hospital Business Net Revenues	RMB153.0 million (US$21.4 million)	11.1% increase from H1 2024 (RMB137.8 million), driven by proton therapy.
Network Business Net Revenues	RMB47.6 million (US$6.6 million)	41.3% decrease from H1 2024 (RMB81.0 million).
Gross Loss Margin	2.1%	Significant improvement from 19.0% in H1 2024.
Net Loss Attributable to Shareholders	RMB27.1 million (US$3.8 million)	Substantial reduction from RMB172.3 million in H1 2024.
Adjusted EBITDA	Negative RMB62.2 million (US$8.7 million)	Improvement from negative RMB148.0 million in H1 2024.

The company's operational focus is clearly shifting value toward the hospital segment, where the advanced proton therapy services reside. The reduction in net loss to RMB27.1 million (US$3.8 million) in H1 2025 shows progress in monetizing these high-value services. Still, the network business saw revenues drop by 41.3% to RMB47.6 million (US$6.6 million).

Finance: draft 13-week cash view by Friday.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Customer Relationships

You're looking at how Concord Medical Services Holdings Limited (CCM) keeps its clients close and engaged, which is key when you're dealing with premium, complex cancer care. The relationship model here is clearly built on high-touch service delivery, especially as they push into high-end technology like proton therapy.

High-touch, personalized care model for premium oncology services

The focus is on delivering specialized, hands-on care. This is the core of the hospital business segment, which saw net revenues of RMB153.0 million (US$21.4 million) in the first half of 2025, an increase of 11.1% year-over-year. This revenue growth in the hospital segment, which includes the Guangzhou Concord Cancer Hospital, suggests that the premium service model is gaining traction, even as total net revenues for H1 2025 were RMB200.6 million (US$28.0 million). The commitment to personalized plans, which adhere to international and domestic guidelines like NCCN and CSCO, is a major part of this high-touch approach. Also, case managers offer one-on-one assistance to streamline the medical process for patients. It's about making a difficult journey manageable.

Long-term clinical support and joint diagnosis for network partners

For the broader network, which historically involved centers in 20 hospitals across 13 provinces, the relationship is one of deep collaboration, not just transactional leasing. Concord Medical Services Holdings Limited provides clinical support services to doctors working in its network centers. This support includes developing treatment protocols for those doctors and organizing joint diagnosis between doctors in the network and clinical research. Long-term clinical support and joint diagnosis for network partners is a way to embed Concord Medical's expertise directly into the partner facilities. The network business revenue, however, saw a significant drop to RMB47.6 million (US$6.6 million) in H1 2025, a decrease of 41.3% compared to H1 2024, which you'll definitely want to watch.

• Clinical support includes developing treatment protocols.
• Organizing joint diagnosis between network doctors.
• Leveraging extensive network of domestic and international experts.

Continuous patient education and prevention programs

Concord Medical Services Holdings Limited profiles itself as a provider of a full cycle of services, which explicitly includes cancer education and prevention. While specific 2025 metrics on program attendance or reach aren't immediately available, this function is crucial for building long-term patient trust and driving early diagnosis, which feeds the premium service pipeline. They are striving to enhance public understanding of precision radiotherapy as part of their forward-looking strategy.

Technology-enabled engagement via the Proton Therapy Large Model

The introduction of advanced technology directly shapes customer interaction and perceived value. Concord Healthcare announced the official release and successful deployment of its self-developed large language model (LLM) focused on proton therapy in May 2025 at the Guangzhou Concord Cancer Hospital. This Proton Therapy Large Model was constructed using multimodal medical data that integrates nearly 10,000 high-quality radiotherapy cases. The deployment followed the completion of China's first proton therapy for Choroidal Malignant Melanoma in July 2025, showing the technology is moving from development to direct patient application. This model is designed to enhance precision and patient outcomes, which is a powerful relationship tool for attracting patients seeking the most advanced care.

Here's a quick look at some key operational and financial data points from the first half of 2025 that frame these customer-facing efforts:

Metric	Value (H1 2025)	Comparison/Context
Total Net Revenues	RMB200.6 million (US$28.0 million)	8.3% decrease vs. H1 2024
Hospital Business Net Revenues	RMB153.0 million (US$21.4 million)	11.1% increase vs. H1 2024
Network Business Net Revenues	RMB47.6 million (US$6.6 million)	41.3% decrease vs. H1 2024
Gross Loss Margin	2.1%	Improved from 19.0% in H1 2024
Proton Therapy LLM Training Data Integration	Nearly 10,000 cases	Used for model enhancement

The shift in revenue mix, with the hospital segment growing while the network segment shrinks, definitely points to where the company is focusing its high-touch, technology-driven customer relationships.

Finance: draft 13-week cash view by Friday.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Channels

You're looking at how Concord Medical Services Holdings Limited (CCM) gets its premium oncology services-from proton therapy to diagnostics-into the hands of patients as of late 2025. The channels are clearly bifurcated, reflecting the company's strategic pivot away from its legacy network model toward owning and operating its own high-tech facilities.

The performance of these channels is best seen through the H1 2025 revenue split. The Hospital Business, which represents the self-owned facilities, is the clear growth engine, while the Network Business, representing partnered centers, is shrinking its revenue contribution significantly.

Channel/Business Segment	H1 2025 Net Revenue (RMB)	H1 2025 Net Revenue (US$)	Year-over-Year Change (H1 2024 vs H1 2025)
Self-owned/Hospital Business	RMB 153.0 million	US$ 21.4 million	+11.1%
Network Business (Partnered)	RMB 47.6 million	US$ 6.6 million	-41.3%
Total Net Revenues	RMB 200.6 million	US$ 28.0 million	-8.3%

The self-owned specialty cancer hospitals are where the high-end, capital-intensive services are centered. Guangzhou Concord Cancer Hospital is the prime example here; its commencement of proton therapy operations was the main driver for the Hospital Business revenue growth of 11.1% in the first half of 2025. This facility is key to delivering multidisciplinary cancer care, including advanced technologies like the state-of-the-art proton therapy system. The company is focusing its capital expenditure here to control the patient experience end-to-end.

The network of partnered hospitals for radiotherapy/imaging centers represents the legacy channel, now showing a sharp decline. While Concord Medical Services Holdings Limited historically operated the largest network of radiotherapy and diagnostic imaging centers in China through long-term arrangements with top-tier hospitals, the H1 2025 revenue from this segment fell by 41.3% to RMB 47.6 million (US$6.6 million). This segment involves providing equipment and managing daily operations on the premises of these hospital partners.

Regarding patient acquisition, the channels rely on a mix of direct and indirect sourcing, though specific 2025 referral numbers aren't public. The growth in the Hospital Business suggests strong direct patient flow, likely driven by the reputation of facilities like the Guangzhou Hospital and the successful deployment of cutting-edge treatments, such as the completion of China's first proton therapy for Choroidal Malignant Melanoma in July 2025. The company's overall strategy is to expand patient access to these advanced technologies.

For online and digital platforms, the focus appears to be on corporate communication and service announcements rather than direct patient booking, based on recent press releases. The company uses its investor relations website and SEC filings to communicate operational milestones, such as the official release of the Proton Therapy Large Model in May 2025. You can expect outreach efforts to be concentrated on enhancing public understanding of precision radiotherapy, which supports patient confidence and, indirectly, patient referrals to their physical centers.

Here's a quick look at the channel focus:

• Self-owned Hospitals: Primary revenue driver, showing 11.1% H1 2025 growth.
• Partnered Centers (Network): Declining revenue contribution, down 41.3% in H1 2025.
• Key Asset: Guangzhou Concord Cancer Hospital, a hub for proton therapy.
• Digital Role: Primarily for corporate updates and building public awareness.

If onboarding new cooperative centers proves difficult, the reliance on the self-owned hospital channel will only intensify.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Customer Segments

You're looking at a company in the middle of a major pivot, moving away from its older leasing model toward owning and operating high-margin specialty facilities. This shift directly targets high-net-worth patients seeking premium, advanced cancer treatment in China. The financial results for the first half of 2025 clearly show where the value is now coming from.

Here's the quick math on the revenue split for the six months ended June 30, 2025, which really highlights this customer focus:

Customer Segment Focus	H1 2025 Net Revenue (RMB)	H1 2025 Net Revenue (USD)	Year-over-Year Change
Hospital Business (Premium/Specialty)	RMB153.0 million	US$21.4 million	11.1% increase
Network Business (Equipment/Services)	N/A (Revenue Plummeted)	N/A	41.3% decrease
Total Company Net Revenues	RMB200.6 million	US$28.0 million	8.3% decrease (Total)

The focus on specialized treatment, particularly proton therapy, is a key differentiator for attracting these premium patients. For instance, the Guangzhou Concord Cancer Center, a subsidiary, completed China's first proton therapy treatment for a patient with choroidal malignant melanoma on July 11, 2025. That kind of first-in-market capability supports the higher pricing structure you'd expect for this service. Also, the underlying technology development is data-intensive; their proprietary proton therapy Large Language Model integrates nearly 10,000 high-quality radiotherapy cases for training. That's serious data depth.

The patient profiles driving this premium segment include:

• High-net-worth individuals seeking advanced oncology care.
• Patients requiring highly specialized treatment like proton therapy.
• Patients with complex or rare malignancies, such as choroidal malignant melanoma.

Then you have the other core segment: domestic Chinese hospitals that rely on Concord Medical Services Holdings Limited for the Network Business's equipment and services, though that segment is clearly under pressure right now. Historically, this network was quite extensive, showing the depth of their prior relationships. What this estimate hides, though, is the current number of active hospital partners as of late 2025, as the latest public data is from the end of 2020.

To give you context on the scale of those hospital partnerships that feed the Network Business:

Network Component	Count (As of Dec 31, 2020)	Geographic Scope
Total Radiotherapy/Diagnostic Centers	27 centers	Spanning over 20 cities
Partner Hospitals Hosting Centers	20 hospitals	Across 13 provinces/regions in China
Company Employees (Total)	595	As of late 2025

Finance: draft 13-week cash view by Friday.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Cost Structure

You're looking at where Concord Medical Services Holdings Limited (CCM) is spending its cash to keep the lights on and, more importantly, to build out that advanced cancer care network. The cost structure is heavily weighted toward asset acquisition and the fixed costs of running high-tech hospitals.

The capital expenditure side is defintely a major drain, reflecting the commitment to high-end technology like proton therapy. For the first half of 2025, capital expenditures totaled RMB100.6 million (US$14.0 million). This was actually lower than the prior year's RMB168.4 million, mainly due to a decrease in deposits for equipment and construction fees for the hospital business. Still, the underlying cost of acquiring and maintaining that state-of-the-art equipment, like the proton therapy systems in Guangzhou and planned for Shanghai and Chengdu, is substantial.

Operating expenses show where the day-to-day running costs lie. General and administrative expenses were RMB119.4 million (US$16.7 million) for the six months ended June 30, 2025. This figure was down from RMB131.2 million in the same period last year, showing some success in cost-cutting efforts.

Here's a quick look at some of the key H1 2025 cost components, all in millions of RMB:

Cost Category	Amount (H1 2025)	Notes
Costs of Revenues (Hospital Business)	RMB157.2 million	Down 9.6% from H1 2024 due to improved HR efficiency and lower consumables/lease costs.
General and Administrative Expenses	RMB119.4 million	Includes staff costs and listing expenses.
Employee Benefit Expenses (within G&A)	RMB51.0 million	A significant portion of the G&A spend.
Selling Expenses	RMB21.0 million	Down from RMB25.0 million in H1 2024.

The investment in future capabilities, specifically around AI and clinical protocols, is a strategic cost. Concord Medical Services Holdings Limited launched its proprietary large language model (LLM) for proton therapy in May 2025 at its Guangzhou Concord Cancer Hospital. This system analyzes over 10,000 high-quality radiotherapy cases, multimodal medical data, and academic literature to optimize tumor targeting.

The costs associated with developing and deploying this technology, alongside refining specialized treatment protocols, are embedded within the overall operating structure. You see the output of this R&D focus in the hospital business, which is now operational with specialized protocols for various malignancies.

The cost structure also reflects the two main segments of the business:

• Costs of revenues for the Network Business were RMB47.7 million (US$6.7 million) in H1 2025.
• This was a 44.8% decrease from RMB86.4 million in H1 2024, linked to reduced sales and installation of medical equipment and software.

Finance: draft 13-week cash view by Friday.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Revenue Streams

You're looking at how Concord Medical Services Holdings Limited (CCM) brings in cash as of late 2025. Honestly, the revenue picture for the first half of 2025 shows a slight dip in total intake, coming in at RMB200.6 million (or US$28.0 million) for the six months ending June 30, 2025. That was down an 8.3% compared to the same period last year. The real story, though, is the shift within the business lines. The hospital segment is actually showing strength, partly because they kicked off proton therapy operations at Guangzhou Concord Cancer Hospital.

Here's the quick math on the two main reported revenue segments for H1 2025:

Revenue Stream Segment	H1 2025 Net Revenue (RMB)	H1 2025 Net Revenue (US$)
Hospital Business services	RMB153.0 million	US$21.4 million
Network Business revenue	RMB47.6 million	US$6.6 million

The hospital business is definitely the core focus now, driving that 11.1% increase in its segment revenue for the first half of 2025, even as the network business saw a significant drop of 41.3%. Still, you need to keep an eye on all the ways Concord Medical Services Holdings Limited (CCM) generates income, as the other streams contribute to the overall top line.

Beyond the reported segments, the revenue model includes several other key areas:

• Proton therapy treatment fees: This is noted as a high-margin, growing segment, directly impacting the RMB153.0 million hospital revenue.
• Sales of high-end, original and imported pharmaceuticals
• Diagnostic imaging and other treatment services fees